Abstract
Several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. A variety of animal and human studies found a dysregulation of endocannabinoid signalling in psychosis. Elevated anandamide levels in schizophrenia patients that are negatively correlated with psychotic symptomatology indicate a protective role, whereas 2-arachidonoylglycerol appears to counteract psychosis-related cognitive impairments. Thus, pharmacological manipulation of the endogenous cannabinoid system might be associated with potential antipsychotic properties. In the present systematic review, both preclinical studies using different animal models of psychosis as well as clinical trials investigating the antipsychotic effects of both cannabidiol and rimonabant are presented together with the possible underlying mechanisms of action. The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.
Keywords: Cannabidiol, rimonabant, endocannabinoid system, schizophrenia, antipsychotics
Current Pharmaceutical Design
Title:Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Volume: 18 Issue: 32
Author(s): Patrik Roser and Ida S. Haussleiter
Affiliation:
Keywords: Cannabidiol, rimonabant, endocannabinoid system, schizophrenia, antipsychotics
Abstract: Several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. A variety of animal and human studies found a dysregulation of endocannabinoid signalling in psychosis. Elevated anandamide levels in schizophrenia patients that are negatively correlated with psychotic symptomatology indicate a protective role, whereas 2-arachidonoylglycerol appears to counteract psychosis-related cognitive impairments. Thus, pharmacological manipulation of the endogenous cannabinoid system might be associated with potential antipsychotic properties. In the present systematic review, both preclinical studies using different animal models of psychosis as well as clinical trials investigating the antipsychotic effects of both cannabidiol and rimonabant are presented together with the possible underlying mechanisms of action. The results predominantly confirm the hypothesis of an antipsychotic activity of both cannabinoids. In comparison, cannabidiol appears to be superior to rimonabant with a pharmacological profile similar to atypical antipsychotic drugs.
Export Options
About this article
Cite this article as:
Roser Patrik and S. Haussleiter Ida, Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884690
DOI https://dx.doi.org/10.2174/138161212802884690 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Levodopa in Parkinson’s Disease: Current Status and Future Developments
Current Neuropharmacology Molecular Effects of L-dopa Therapy in Parkinson’s Disease
Current Genomics In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson’s Disease
Current Neuropharmacology A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Retraction Notice: Clinical Strategies for Preventing Postoperative Nausea and Vomiting After Middle Ear Surgery in Adult Patients
Current Drug Safety Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology HTR2A Gene Variants and Psychiatric Disorders: A Review of Current Literature and Selection of SNPs for Future Studies
Current Medicinal Chemistry The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions
Current Drug Targets Impulsive and Compulsive Behaviors During Dopamine Replacement Treatment in Parkinson’s Disease and Other Disorders
Current Drug Safety New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine